And I am hopeful that we are able to specifically tackle insulin prices later this year. But we can't ignore the business practices of the companies that have come before us today. Part of how we tackle drug prices relates to that need to get transparency and that need to take on the aspect of greed. Thank you very much, Senator Baldwin. Senator Cassidy. I'll go ahead and take my questions now. (05:39–05:51)
CLAIM
Asserts that addressing drug prices requires transparency and tackling greed.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
